Recent Articles from GlobeNewswire

NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) --

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data showing BBO-10203 selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. In addition, combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well tolerated dose levels in a panel of KRAS mutant models. The data were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) --

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases

NASP data highlight reduction in disease burden among people living with uncontrolled gout

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Quanex (NYSE:NX) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fluor (FLR) To Contact Him Directly To Discuss Their Options

Revenues of INR 10,533 Million. EBITDA of INR 2,361 Million.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In V.F. Corporation (VFC) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options

World Champion Marion Clignet’s Journey: One More Kilometer, 30 Years on the Road.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Quantum (QMCO) To Contact Him Directly To Discuss Their Options

FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease (NERD) have been published in the American Journal of Gastroenterology. The article, titled “Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease”, underscores the significant burden of nighttime GERD symptoms and the potential role of VOQUEZNA in addressing this aspect of the disease.

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results showed consistently higher objective response rates (ORR) and longer progression-free survival (PFS) across subgroups in patients treated with n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide) compared to everolimus, reinforcing its previously reported efficacy profile. Data were shared by study investigator, Jaume Capdevila, MD, PhD, in both oral and poster presentations at the 2025 North American Neuroendocrine Tumor Society (NANETS) Annual Multidisciplinary NET Medical Symposium, held October 23-25, 2025, in Austin, Texas.As previously announced at ENETS 2025, the COMPETE trial, which included a total of 309 patients randomized to either 177Lu-edotreotide (n=207) or everolimus (n=102), met its primary endpoint of progression-free survival, or PFS, (23.9 vs. 14.1 months; p=0.022; HR 0.67, 95% CI [0.48, 0.95]). At ESMO 2025, ITM announced that the COMPETE trial also met a key secondary endpoint of objective response rate (ORR) (21.9% vs 4.2%, p<0.0001).In this analysis of the COMPETE trial presented at NANETS 2025, the key findings showed:

New York, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Ave Acquisition Corporation (Nasdaq: HAVAU) (the “Company”) announced today the closing of its initial public offering of 14,500,000 units at $10.00 per unit. The gross proceeds from the offering were $145 million before deducting underwriting discounts and estimated offering expenses. The units were listed on the Nasdaq Global Market (“Nasdaq”) and began trading under the ticker symbol “HAVAU” on October 23, 2025. Each unit consists of one Class A ordinary share and one right to receive one-tenth of one Class A ordinary share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols “HAVA” and “HAVAR”, respectively.

CHARLOTTE, N.C., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or prefunded warrants in lieu thereof) and common warrants (the “Offering”). The Company will allocate proceeds from the offering toward the global expansion of IM8, driven by its explosive growth, and the strategic accumulation of Bitcoin (BTC) as part of its pioneering dual-pronged health and wealth strategy.

Learning Resources, Inc. and hand2mind, Inc. v. President Donald J. Trump, et al.; President Donald J. Trump, et al. v. V.O.S. Selections, Inc., et al.

EAGLE, Idaho, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its third quarter 2025 financial results on Wednesday, November 5, 2025.

LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- GBank Financial Holdings Inc. (the "Company") (Nasdaq: GBFH), the parent company for GBank (the "Bank"), today announced it has updated the date for the release its third quarter 2025 financial results from after the market closes on Monday, October 27, 2025 to after the market closes on Tuesday, October 28, 2025.  The timing of the quarterly earnings call remains unchanged on Wednesday, October 29, 2025, at 10:00 a.m., PST. Interested parties can participate remotely via Internet connectivity. There will be no physical location for attendance.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) --

New Executive Leadership, Open Market Stock Purchases, and Minimum Equity Ownership Policy Further Align Shareholder Interests

Scottsdale, AZ, Oct. 24, 2025 (GLOBE NEWSWIRE) -- American Home Water & Air, a residential water and air systems provider headquartered in Scottsdale, today announced the expansion of its operational service network across the greater Scottsdale region. The development is intended to strengthen the company’s capacity to deliver water treatment, reverse osmosis, water softener, AC repair, furnace repair, and HVAC maintenance services to local homeowners.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Semtech Corporation (NASDAQ: SMTC).

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) will hold a conference call at 8:30 a.m. Eastern Time on Friday, November 7, 2025 to discuss its 2025 third quarter results, which will be announced after the close of markets on Thursday, November 6, 2025 and will be available at that time on its website at www.fairfax.ca. The call, consisting of a presentation by the company followed by a question period, may be accessed at 1 (800) 369-2143 (Canada and U.S.) or 1 (312) 470-0063 (International) with the passcode “FAIRFAX”.

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company will release its financial and operating results for the third quarter of 2025 prior to the market open on Thursday, November 13, 2025. The Company will then host a conference call to review the results later that day, at 1:00 pm Eastern Time (“ET”). Those wishing to join the call can do so using the telephone numbers listed below. The call will also be webcast and available on the Company’s website at www.discoverysilver.com.

Enzon and Viskase stockholders will respectively own 45% and 55% of the combined company

GREAT NECK, N.Y., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that its net income for the three months ended September 30, 2025 was approximately $1,202,000, or $0.11 per basic and diluted share (based on approximately 11.4 million weighted-average outstanding common shares), as compared to approximately $1,399,000, or $0.12 per basic and diluted share (based on approximately 11.4 million weighted-average outstanding common shares), for the three months ended September 30, 2024, a decrease of $197,000, or 14.1%. This decrease is primarily attributable to a decrease in revenue, partially offset by a decrease in interest expense.

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the "Company" or "Rivalry") (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for digital-first players, is pleased to announce that it has closed the third tranche of its non-brokered private placement (the "Private Placement") previously announced on September 29, 2025. The Company issued 29,937,930 units ("Units") at a price of C$0.05 per Unit (the "Offering Price"), for gross proceeds of C$1,496,896.50. Each Unit consists of one (1) subordinate voting share in the capital of the Company (each, a "SV Share") and one (1) SV Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable into one (1) SV Share (each, a "Warrant Share") at a price of C$0.10 per Warrant Share until October 8, 2027. The SV Shares, Warrants and Warrant Shares are subject to a four-month statutory hold period, in accordance with applicable securities legislation. The Company intends to use the net proceeds from the Private Placement for corporate development and general working capital purposes. The Company may complete a final tranche of the Private Placement on or prior to November 15, 2025.

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) --

Together, IGEL OS and Palo Alto Networks’ Prisma® Browser deliver consistent, frictionless Zero Trust access to SaaS, web, and private applications on any device

Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences:

~ With Substantial Cash on Balance Sheet, Company Set to Reignite Growth and Drive Shareholder Value on Path to Profitability ~

53-Years of Consecutive Dividend Increases

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following:

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – 

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) --

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options

PASCAGOULA, Miss., Oct. 24, 2025 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division successfully completed the second builder’s sea trials for guided missile destroyer Ted Stevens (DDG 128), building on the success of the initial trials conducted at the end of September. The Arleigh Burke-class (DDG 51) destroyer spent multiple days in the Gulf of America testing the ship’s main propulsion, combat systems and other critical systems in preparation for the future acceptance trials.

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation –

Honored for game-based learning innovations K12 ELA Village and K12 Coordinate Islands world for Minecraft Education

WASHINGTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Lyons Broadcast PR, a national leader in Satellite Media Tours (SMTs), broadcast media relations, and video production proudly celebrates its 20th anniversary this year. For two decades, the award-winning firm has helped associations, nonprofits, brands, and federal agencies reach millions of key audiences through expertly produced satellite media tours and customized broadcast campaigns.

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Transaction in Own Shares   

BH-30643, a first-in-class, macrocyclic OMNI-EGFR™ inhibitor, demonstrates preliminary anti-tumor activity across a variety of advanced EGFR-mutant non-small cell lung cancers with complex and difficult-to-treat resistance mutations

Surfshark, a cybersecurity company, launches a new feature called the web content blocker that focuses on safeguarding every household when browsing online. It allows you to filter various websites based on categories provided, lock them using 2FA (Two-factor Authentication), and help protect family members from potential online threats caused by curiosity or carelessness.

Expansion to energize investment in historic New Mexico community.

CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced part A data from the ongoing Phase 1 study of FX-909, a first-in-class orally available small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), the master regulator of the luminal lineage, in locally-advanced or metastatic urothelial cancer (UC). FX-909 demonstrated early signs of clinical benefit in patients with advanced urothelial carcinoma as a monotherapy with a favorable safety profile.

Shelton, CT, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Hubbell Incorporated (NYSE:HUBB) today declared a 8% increase in its common stock dividend rate. The new annual payment of $5.68 per share, or $1.42 per quarter, compares to the former rate of $5.28 per share, or $1.32 per quarter. The dividend will be paid on December 15, 2025 to shareholders of record on November 28, 2025.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Newsweek, in partnership with sustainability data experts Plant-A Insights Group and GIST Impact, announced today the 2026 ranking of America’s Greenest Companies, recognizing 450 U.S. organizations that are leading the way in environmental sustainability, transparency, and impact reduction.

First and Only FDA-Approved, Ready-to-Use Clonidine Oral Solution for Hypertension Control in Adult Patients

Expansion Supports Middle East Growth, Abu Dhabi Acquisition and Accelerated Commercialization of AI-driven Cybersecurity Advanced Technology

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter securities between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Marex Group PLC (“Marex” or the “Company”) (NASDAQ: MRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Marex securities between May 16, 2024 and August 5, 2025, inclusive (the “Class Period”).

DES MOINES, Iowa, Oct. 24, 2025 (GLOBE NEWSWIRE) --

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Marex Group plc (“Marex” or “the Company”) (NASDAQ: MRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against WPP plc (“WPP” or “the Company”) (NYSE: WPP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that Ankur Keswani joined the firm as Managing Director.

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation (“Quantum” or the “Company”)(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc (“Tronox” or the “Company”) (NYSE: TROX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.